Navigation Links
Mouse Anti-Human MYO7A Monoclonal Antibody, Unconjugated, Clone 1D3 from Abnova Corporation

ProductsMouse Anti-Human MYO7A Monoclonal Antibody, Unconjugated, Clone 1D3 from Abnova Corporation
Company Abnova Corporation
Item Mouse Anti-Human MYO7A Monoclonal Antibody, Unconjugated, Clone 1D3
Price 
Description Mouse monoclonal antibody raised against a partial recombinant MYO7A.
NCBI Entrez Gene ID = MYO7A
Info Abnova CorporationAbnova Corporation
Abnova Corporation (HQ)
9th Fl., No. 108, Jhouzih St.
Neihu District, Taipei
114 Taiwan R.O.C.
Tel: +886-2-8751-1888
Fax: +886-2-8751-1166

Abnova GmbH
Boxbergring 107
69126 Heidelberg
Germany
Tel: +49 6221 3632226
Fax: +49 6221 825878

Customer Service: +886-2-8751-1888
Fax Number: +886-2-8751-1166
Web Site: http://www.abnova.com.tw
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Mouse Anti-Amodiaquine Monoclonal Antibody, Unconjugated, Clone 6D10 from AntibodyShop A/S
2. Mouse Anti-Protein S Monoclonal Antibody, Unconjugated, Clone HYB 232-02 from Abcam
3. Mouse Anti-Mouse Glutathione S-transferase M1 (GSTM1) Monoclonal Antibody, Unconjugated from Lifespan Biosciences
4. Mouse Anti-Human S-100 alpha/beta chain Monoclonal Antibody, Unconjugated, Clone 8B10 from Santa Cruz Biotechnology, Inc.
5. Rapid-Screen Arrayed cDNA Library Panels Master Plates -Mouse Testis from OriGene Technologies
6. Rapid-Screen Arrayed cDNA Library Panels Master Plates -Mouse Brain (adult) from OriGene Technologies
7. Rapid-Screen Arrayed cDNA Library Panels Master Plates -Mouse Embryo (12.5 - day) from OriGene Technologies
8. Rapid-Screen Arrayed cDNA Library Panels Master Plates -Mouse Embryo (19 - day) from OriGene Technologies
9. Rapid-Screen Arrayed cDNA Library Panels Master Plates -Mouse Thymus from OriGene Technologies
10. Mouse Anti-Human Complement factor B Monoclonal Antibody, Unconjugated, Clone 9B6 from AntibodyShop A/S
11. Mouse Anti-Human Choriongonadotropin (hCG) Monoclonal Antibody, Unconjugated, Clone 5F10 from AntibodyShop A/S
... The pYD1 Yeast Display Vector is specifically ... on the surface of Saccharomyces cerevisiae. Displayed ... to interact with known or putative ligands. ... which consists of two domains Aga1 and ...
... (Aph-1aL,S Loop 92-115), O2F1 Affinity Purified ... multiprotein complex consisting of presenilin, nicastrin, ... are necessary for full proteolytic activity. ... of a number of integral membrane ...
TGase3 (S-20)...
Mouse monoclonal [HYB 232-02] to Protein S ( Abpromise for all tested applications). entrezGeneID: 5627 SwissProtID: P07225...
Biology Products:
(Date:12/16/2009)... that short-term, seasonal exposure to pesticides in rivers ... of wild salmon populations. In addition to the ... that exposure to commonly used pesticides may further ... , "Major efforts are currently underway to ... recover depressed populations," says David Baldwin of the ...
(Date:12/16/2009)... a global provider of business process outsourcing (BPO) services, ... Awards Top 100 IT project of 2009 for its ... for iQor. ,, "We are honored to be recognized ... president and CEO of iQor. "TeQ21 is completely transforming ... faster, smarter and with the added security biometrics provides. ...
(Date:12/16/2009)... N.J., Dec. 3 BIO-key International, ... in wireless public safety and finger-based biometric ... its shareholders at a Special Shareholder Meeting ... company,s Law Enforcement Division to Interact911 Mobile ... were cast in favor and 1.2% were ...
Breaking Biology News(10 mins):Even at sublethal levels, pesticides may slow the recovery of wild salmon populations 2iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3Concussion experts 3A For kids no sports no schoolwork no text messages 48183 1Concussion experts 3A For kids no sports no schoolwork no text messages 48183 2New research program BioInterfaces launched 8742 1New research program BioInterfaces launched 8742 2Quest Diagnostics to Speak at the William Blair 26 Company 29th Annual Growth Stock Conference 48179 1Quest Diagnostics to Speak at the William Blair 26 Company 29th Annual Growth Stock Conference 48179 2
... salt cedar eatersthan beetles from Greece. At least ... Uzbekistan salt cedar beetles being released by the ... those released onthe salt cedar stands near Lake ... said Vanessa Carney, Experiment Station entomologyresearch associate. , ...
... may have broader implications for understanding kidney disorders, ... have identified a second gene that gives rise ... affects multiple organs. The Children's Hospital team previously ... , The researchers found that mutations in the ...
... arterial blockages related to diabetes, smoking, obesity and ... rate. Yet physicians may be too quick to ... preventable, according to the International Diabetes Foundation. , ... are more dangerous and more expensive than revascularization, ...
Other Biology News:Better beetle sought for salt cedar control 2Better beetle sought for salt cedar control 3Gene discovery may shed light on kidney disease 2Epidemic of unneeded amputations 2
(Date:12/16/2009)... Martek Biosciences Corporation (Nasdaq: MATK ) ... and fiscal year ended October 31, 2009. Revenues for ... $90.4 million in the fourth quarter of fiscal 2008. ... share, for the fourth quarter of fiscal 2009, a ... diluted share, in last year,s fourth quarter. The ...
(Date:12/16/2009)... microgears in suspended solution by swimming , ... ... Scientists at the U.S. Department of Energy’s (DOE) Argonne National ... bacteria can turn microgears when suspended in a solution, providing ... , , ,“The gears are a million times more massive ...
(Date:12/16/2009)... -- Decision Resources, one of the world,s leading ... issues, finds that, according to responses from surveyed ... (both interleukin inhibitors) will capture 22 percent of ... market for moderate to severe psoriasis. Among these ... nearly three times as much patient share as ...
(Date:12/16/2009)... to Special Protocol Assessment with the Food ... 16 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... a global biopharmaceutical company focused on oncology ... by its partner Keryx Biopharmaceuticals Inc. ("Keryx") ... clinical trial for perifosine (KRX-0401), the Company,s ...
Breaking Biology Technology:Martek Announces Fourth Quarter and FY 2009 Financial Results 2Martek Announces Fourth Quarter and FY 2009 Financial Results 3Martek Announces Fourth Quarter and FY 2009 Financial Results 4Martek Announces Fourth Quarter and FY 2009 Financial Results 5Martek Announces Fourth Quarter and FY 2009 Financial Results 6Martek Announces Fourth Quarter and FY 2009 Financial Results 7Martek Announces Fourth Quarter and FY 2009 Financial Results 8Martek Announces Fourth Quarter and FY 2009 Financial Results 9Martek Announces Fourth Quarter and FY 2009 Financial Results 10Martek Announces Fourth Quarter and FY 2009 Financial Results 11Martek Announces Fourth Quarter and FY 2009 Financial Results 12Martek Announces Fourth Quarter and FY 2009 Financial Results 13Martek Announces Fourth Quarter and FY 2009 Financial Results 14Argonne Scientists Use Bacteria to Power Simple Machines 2Argonne Scientists Use Bacteria to Power Simple Machines 3In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 2In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 2AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 4AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 5